CTOs on the Move

Morphotek

www.morphotek.com

 
Morphotek is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.morphotek.com
  • 210 Welsh Pool Rd Welsh Pool
    Exton, PA USA 19341
  • Phone: 610.423.6100

Executives

Name Title Contact Details

Similar Companies

Kamiya Biomedical Company

Kamiya Biomedical Company is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intralytix

Intralytix, Inc. is a biotechnology company focused on the production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

LyGenesis

LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient`s lymph nodes to be used as bioreactors to regrow functioning ectopic organs.

Complete Testing Solutions

Complete Testing Solutions is a Gilbert, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coherus Biosciences

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team`s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.